NCT06451952 · RECRUITING
Virtual Darkness Theraphy for Agitation in Dementia
This trial is testing whether blocking blue-wavelength light in the evening and overnight — called virtual darkness therapy — reduces agitation in people with dementia who are hospitalized. Patients wear amber-tinted glasses or are placed in blue-light-filtered environments from 7pm to 8am. Researchers measure agitation levels before and after 14 days. This is a Phase NA trial, meaning it is exploratory and feasibility-focused, not yet a large-scale proven treatment.
You may qualify if
- Patients admitted to NKS Olaviken gerontopsychiatric hospital
- Diagnosis of dementia, all stages and etiologies,
- ≥50 years
- both genders
- Clinically significant agitation (CMAI ≥45)
You're excluded if
- Total blindness/diminished bilateral red reflex.
- Use of melatonin
- Clinically significant pain (MOBID-2≥3)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-04-11